Evaluation of Self-Illuminating Nanoconjugates Against Pancreatic Ductal Adenocarcinoma
Marcelina Abal-Sanisidro1,2,3, Laura Ruiz-Cañas4,5, Sandra Batres-Ramos4,5
1Nano-Oncology and Translational Therapeutics Group, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital (CHUS), SERGAS, Santiago de Compostela, A Coruña, 15706, Spain.
Introduction:
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause of cancer-related mortality by 2030, underscoring the need for new therapeutic approaches. While photodynamic therapy (PDT) has proven to be efficient for treating superficial solid tumors, conventional laser-dependent PDT is limited by poor tissue penetration. To address this challenge, we developed a novel self-illuminating nanoconjugate platform (SI-NCs) capable of activating PDT without external light.
Methods:
We engineered SI-NCs composed of the bioluminescent enzyme RLuc8 conjugated to quantum dots (QDots 705) to generate internal light for activating the FDA-approved photosensitizer verteporfin. We then evaluated SI-NC photophysical properties and assessed their ability to induce localized antitumor activity in PDAC models.
Results:
SI-NCs were successfully synthesized and characterized, demonstrating efficient bioluminescence resonance energy transfer and activation of verteporfin. In vitro studies in immortalized pancreatic cancer cell lines and patient-derived primary cultures revealed the mechanism of action and confirmed antitumor efficacy of bioluminescent-activated PDT.
Conclusion:
In vivo testing in patient-derived xenograft (PDX) models validated the therapeutic potential of SI-NCs, supporting this self-illuminating platform as a promising strategy to overcome light-penetration barriers and enhance PDT for PDAC treatment.
Insights
Researchers developed self-illuminating nanoconjugates (SI-NCs) to activate photodynamic therapy (PDT) for pancreatic cancer. This novel approach overcomes light penetration limits, offering a promising new treatment for pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Biomedical Engineering
- Oncology
- Nanotechnology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality with limited treatment options.
- Conventional photodynamic therapy (PDT) is hindered by poor light penetration in deep tissues.
- Novel therapeutic strategies are crucial for improving PDAC treatment outcomes.
Purpose of the Study:
- To develop a novel self-illuminating nanoconjugate (SI-NC) platform for light-free photodynamic therapy (PDT).
- To overcome the limitations of external light penetration in conventional PDT for pancreatic cancer treatment.
- To evaluate the efficacy of SI-NCs in preclinical models of pancreatic ductal adenocarcinoma (PDAC).
Main Methods:
- Engineered SI-NCs by conjugating RLuc8 enzyme to Qdots 705 for internal light generation.
- Utilized internal light to activate the photosensitizer verteporfin for targeted PDT.
- Assessed SI-NC photophysical properties and in vitro/in vivo antitumor activity in PDAC models.
Main Results:
- Successfully synthesized and characterized SI-NCs, demonstrating efficient bioluminescence resonance energy transfer.
- Confirmed verteporfin activation and localized antitumor effects in vitro using pancreatic cancer cell lines.
- Validated therapeutic potential in patient-derived xenograft (PDX) models, showing significant antitumor activity.
Conclusions:
- SI-NCs represent a promising platform for overcoming light penetration barriers in PDT.
- Bioluminescent-activated PDT using SI-NCs offers a novel and effective therapeutic strategy for PDAC.
- This approach holds potential for enhancing PDT efficacy in challenging solid tumor treatments.
